Trials / Unknown
UnknownNCT03993743
A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma
An Open-label, Dose Escalation Clinical Study to Access the Safety and Clinical Activity of CD147-targeted CART by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells by hepatic artery infusions in patients with advanced hepatocellular carcinoma.
Detailed description
Patients autologous T cells are activated and then engineered to express chimeric antigen receptors (CARs) specific for CD147(CD147-CART). CAR-T cells are expanded in culture and returned to the patient by hepatic artery infusion at specific cell doses. Four CD147-CART doses patient are planned at 1-week intervals. Tumor biopsies will be obtained at the time of the initial diagnostic angiogram and during the first infusion session. Serum cytokine level and CAR-T cell number will be measured in whole treatment session.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD147-CART | Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery. |
Timeline
- Start date
- 2019-05-27
- Primary completion
- 2020-10-27
- Completion
- 2022-05-27
- First posted
- 2019-06-21
- Last updated
- 2019-08-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03993743. Inclusion in this directory is not an endorsement.